Skip to main content
CMPX logo

CMPX · Compass Therapeutics, Inc. · Executive Compensation

Track CMPX — free
$0.67 -0.01 (-1.25%)
Market Cap
$122.19M
Shares
180.09M
Volume · Nov 19 1.68M Avg daily vol (3M) 3.86M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025
Executive Total
Thomas J. Schuetz $5,097,150
Jonathan E. Anderman $1,427,800
Barry Shin $1,394,500
Fiscal 2024
Executive Total
Vered Bisker-Leib $6,433,665
Thomas J. Schuetz $3,093,057
Barry Shin $1,220,942
Jonathan E. Anderman $893,635
Fiscal 2023
Executive Total
Thomas J. Schuetz $4,873,206
Vered Bisker-Leib $4,067,284
Jonathan E. Anderman $707,948
Barry Shin —
Fiscal 2022
Executive Total
Thomas J. Schuetz $2,115,185
Vered Bisker-Leib $1,724,739
Susan Kalled $462,030
Fiscal 2021
Executive Total
Thomas J. Schuetz $5,258,000
Vered Bisker-Leib $4,450,000
Susan Kalled $1,781,616
Fiscal 2020
Executive Total
Vered Bisker-Leib $2,571,579
Thomas J. Schuetz $2,556,793
Susan Kalled —
Fiscal 2019
Executive Total
Thomas J. Schuetz $1,373,843
Vered Bisker-Leib $1,055,034

Executive changes

Person Change Filed
Neil Lerner Appointed 2024-12-10
Barry Shin Appointed 2024-12-10
Thomas Schuetz Appointed 2024-05-28
Vered Bisker-Leib
“Dr. Bisker-Leib’s resignation from the Board of Directors is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2024-05-28
Vered Bisker-Leib
“Dr. Bisker-Leib’s resignation from the Board of Directors is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2024-05-28
Vered Bisker-Leib, PhD Appointed 2024-01-09
Vered Bisker-Leib, PhD Appointed 2024-01-09
Richard S. Lindahl Appointed 2023-04-24
Richard S. Lindahl Appointed 2023-04-24
David Wurzer
“Mr. Wurzer’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2023-02-24
David Wurzer Appointed 2023-02-10
Stephen Squinto, Ph.D.
“Dr. Squinto’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2022-08-19
Mary Ann Gray Appointed 2022-04-26
Ellen Chiniara Appointed 2022-04-26
Julie Sunderland
“Ms. Sunderland’s resignation was not the result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
Resigned 2021-12-21
Miranda Toledano Appointed 2021-06-30

Leadership

Key facts CIK 1738021 CUSIP 20454B104 13F (30d) 187 filings 169 filers Visit website Investor relations